Skip to main content

Table 3 Competing risks regression for the association between RS and iLRR

From: Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer

Treatment group

Competing risk regression for iLRR

60-month cumulative incidence of iLRR (95% CI)

HR (95% CI)

P

Entire cohort

 RS < 25

1.0 (reference)

 

1.8% (1.0–3.0%)

 RS ≥25

1.14 (0.39–3.36)

0.81

3.2% (1.0–7.6%)

Hormonal therapy without chemotherapy

 RS < 25

1.0 (reference)

 

1.9% (1.0–3.3%)

 RS ≥25

3.66 (1.07–12.5)

0.04

10.3% (2.2–25.7%)

  1. CI confidence interval, HR hazard ratio, iLRR isolated locoregional recurrence, RS recurrence score